Capital Group Investment Management’s AbbVie ABBV Stock Holding History

Capital Group Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41M	Buy	9,584 +685	+8%	+$147K	0.36%	66
2026 Q1	$1.94M	Buy	8,899 +3,447	+63%	+$765K	0.33%	84
2025 Q4	$1.25M	Buy	5,452 +1,395	+34%	+$318K	0.2%	105
2025 Q3	$939K	Hold	4,057	–	–	0.16%	116
2025 Q2	$753K	Buy	4,057 +988	+32%	+$184K	0.13%	118
2025 Q1	$643K	Sell	3,069 -4,606	-60%	-$895K	0.13%	121
2024 Q4	$1.36M	Sell	7,675 -435	-5%	-$80K	0.26%	91
2024 Q3	$1.6M	Buy	8,110 +199	+3%	+$37.1K	0.32%	83
2024 Q2	$1.36M	Sell	7,911 -9,328	-54%	-$1.55M	0.29%	83
2024 Q1	$3.14M	Sell	17,239 -35,803	-67%	-$6.17M	0.56%	50
2023 Q4	$8.22M	Sell	53,042 -71,391	-57%	-$10.4M	0.86%	28
2023 Q3	$18.5M	Sell	124,433 -11,591	-9%	-$1.7M	1.21%	23
2023 Q2	$18.3M	Buy	136,024 +132,746	+4,050%	+$19.5M	0.91%	40
2023 Q1	$522K	Sell	3,278 -4,331	-57%	-$662K	0.03%	181
2022 Q4	$1.23M	Buy	+7,609	New	+$1.17M	0.05%	143

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Group Investment Management's ABBV Position: Q2 2026 in Review

Capital Group Investment Management increased its AbbVie (ABBV) stake by 7.7% in Q2 2026, buying an estimated $147K and bringing the position to 9,584 shares worth $2.41M. The position accounts for 0.36% of the portfolio, ranked #66.

Capital Group Investment Management first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $18.5M in Q3 2023. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Capital Group Investment Management held 9,584 shares of AbbVie worth $2.41M as of Q2 2026.
Capital Group Investment Management bought 685 AbbVie shares in Q2 2026, an estimated $147K.
AbbVie made up 0.36% of Capital Group Investment Management's portfolio in Q2 2026, its #66 holding.
Capital Group Investment Management first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
Capital Group Investment Management's AbbVie position peaked at $18.5M in Q3 2023.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.